TCIM
EPZM

TIAA CREF Investment Management’s Epizyme, Inc EPZM Stock Holding History

TIAA CREF Investment Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.26M Buy
101,959
+2,042
+2% +$22.8K ﹤0.01% 2216
2018
Q4 		$615K Sell
99,917
-951
-0.9% -$7.26K ﹤0.01% 2480
2018
Q3 		$1.07M Sell
100,868
-65,340
-39% -$746K ﹤0.01% 2391
2018
Q2 		$2.25M Buy
166,208
+55,265
+50% +$860K ﹤0.01% 2109
2018
Q1 		$1.97M Sell
110,943
-1,901
-2% -$32.1K ﹤0.01% 2112
2017
Q4 		$1.42M Buy
112,844
+2,832
+3% +$41.2K ﹤0.01% 2298
2017
Q3 		$2.1M Sell
110,012
-38,475
-26% -$587K ﹤0.01% 2143
2017
Q2 		$2.24M Buy
148,487
+40,535
+38% +$613K ﹤0.01% 2109
2017
Q1 		$1.85M Sell
107,952
-6,558
-6% -$87.3K ﹤0.01% 2183
2016
Q4 		$1.39M Sell
114,510
-12,467
-10% -$130K ﹤0.01% 2377
2016
Q3 		$1.25M Sell
126,977
-3,056
-2% -$27.9K ﹤0.01% 2424
2016
Q2 		$1.33M Buy
130,033
+13,905
+12% +$155K ﹤0.01% 2375
2016
Q1 		$1.41M Buy
116,128
+20,124
+21% +$204K ﹤0.01% 2281
2015
Q4 		$1.54M Hold
96,004
– – ﹤0.01% 2324
2015
Q3 		$1.24M Sell
96,004
-3,469
-3% -$70K ﹤0.01% 2435
2015
Q2 		$2.39M Buy
99,473
+53,213
+115% +$1.02M ﹤0.01% 2191
2015
Q1 		$869K Hold
46,260
– – ﹤0.01% 2686
2014
Q4 		$873K Sell
46,260
-1,912
-4% -$44.7K ﹤0.01% 2729
2014
Q3 		$1.31M Hold
48,172
– – ﹤0.01% 2488
2014
Q2 		$1.5M Buy
48,172
+25,448
+112% +$599K ﹤0.01% 2477
2014
Q1 		$517K Sell
22,724
-980
-4% -$29.7K ﹤0.01% 2926
2013
Q4 		$493K Hold
23,704
– – ﹤0.01% 2965
2013
Q3 		$951K Buy
23,704
+334
+1% +$11.3K ﹤0.01% 2635
2013
Q2 		$657K Buy
+23,370
New +$600K ﹤0.01% 2829

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

TIAA CREF Investment Management's EPZM Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Epizyme, Inc (EPZM) stake by 2% in Q1 2019, buying an estimated $22.8K and bringing the position to 101,959 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #2216.

TIAA CREF Investment Management first reported a position in EPZM in Q2 2013 and has held it in 24 quarters since. The position peaked at $2.39M in Q2 2015. 121 funds tracked by Wall St. Rank hold EPZM as of Q1 2019.

  • TIAA CREF Investment Management held 101,959 shares of Epizyme, Inc worth $1.26M as of Q1 2019.
  • TIAA CREF Investment Management bought 2,042 Epizyme, Inc shares in Q1 2019, an estimated $22.8K.
  • Epizyme, Inc made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2216 holding.
  • TIAA CREF Investment Management first reported a position in Epizyme, Inc in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Epizyme, Inc position peaked at $2.39M in Q2 2015.
  • 121 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.